US2018271959A1PendingUtilityA1

Sustained release poloxamer containing pharmaceutical compositions

61
Assignee: ALLERGAN INCPriority: Feb 22, 2008Filed: May 25, 2018Published: Sep 27, 2018
Est. expiryFeb 22, 2028(~1.6 yrs left)· nominal 20-yr term from priority
A61P 17/00A61K 47/34A61K 38/4893A61K 2800/95A61K 41/0052A61K 2800/594A61K 2800/52A61K 47/60A61K 9/0019A61K 8/90A61K 38/48C12Y 304/24069A61K 47/643A61K 8/042A61K 9/0024A61Q 19/08A61K 47/6903A61K 2800/91A61K 8/66A61K 9/08A61K 8/64A61K 2800/56A61K 41/00C07K 14/00A61K 9/06Y02A50/469Y02A50/30
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose.

Claims

exact text as granted — not AI-modified
I claim: 
     
         1 . A thermoreversible, thermoplastic, pharmaceutical composition consisting of: (a) a biologically active botulinum toxin, and; (b) a thermoplastic poloxamer, wherein the thermoreversible, thermoplastic, pharmaceutical composition is transitionable from a low viscosity liquid solution for easy passage through a needle prior to administration by injection to a patient to a gel after administration. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the poloxamer is a poloxamer 407. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the biologically active botulinum toxin is a botulinum toxin type A. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the biologically active botulinum toxin is a botulinum toxin type B. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the biologically active botulinum toxin is a neurotoxic component of a botulinum toxin. 
     
     
         6 . A method for treating a medical or cosmetic condition, the method comprising the step of administering to a patient a thermoreversible, thermoplastic, pharmaceutical composition consisting of a biologically active botulinum toxin and a thermoplastic poloxamer,
 wherein the thermoreversible, thermoplastic, pharmaceutical composition is transitionable from a low viscosity liquid solution for easy passage through a needle prior to administration by injection to a patient to a gel after administration.   
     
     
         7 . The method of  claim 6 , wherein the thermoplastic poloxamer is a poloxamer 407. 
     
     
         8 . The method of  claim 6 , wherein treating the medical or cosmetic condition comprises treating at least one of glabellar lines, nasolabial lines, crows feet, marionette lines and horizontal lines of the forehead. 
     
     
         9 . The method of  claim 6 , wherein treating the medical or cosmetic condition comprises treating at least one of overactive bladder, hyperhidrosis, benign prostatic hyperplasia and a dystonia. 
     
     
         10 . The method of  claim 6 , further comprising the step of placing a cooling or heating element over an area of administration before or after the administration step to warm or cool the area in order to decrease or increase the viscosity of the administered pharmaceutical composition, in situ, in the patient. 
     
     
         11 . A method for treating a medical or cosmetic condition, the method comprising the steps of:
 administering to a patient a thermo-reversible thermoplastic, pharmaceutical composition consisting a biologically active botulinum toxin and a thermoreversible, thermoplastic poloxamer,   wherein the poloxamer stabilizes the botulinum toxin so that the botulinum toxin retains biological activity upon release of the botulinum toxin from the pharmaceutical composition in vivo;   and wherein the thermo-reversible, thermoplastic, pharmaceutical composition is transitionable from a low viscosity liquid solution for easy passage through a needle prior to administration by injection to a patient to a gel after administration.   
     
     
         12 . The method of  claim 11 , wherein the poloxamer is a poloxamer 407. 
     
     
         13 . The method of  claim 11 , wherein treating the medical or cosmetic condition comprises administration to at least one of glabellar lines, nasolabial lines, crows feet, marionette lines and horizontal lines of the forehead.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.